MODERN POSSIBILITIES OF THERAPY OF TYPE 2 DIABETES MELLITUS PATIENTS. EFFECTIVENESS AND CARDIOSAFETY OF ALOGLIPTIN FROM THE POINT OF VIEW OF EVIDENCE-BASED MEDICINE

MODERN POSSIBILITIES OF THERAPY OF TYPE 2 DIABETES MELLITUS PATIENTS. EFFECTIVENESS AND CARDIOSAFETY OF ALOGLIPTIN FROM THE POINT OF VIEW OF EVIDENCE-BASED MEDICINE

According to the IDF (2016) 1 of 11 adult patients suffers from diabetes mellitus (DM). The total number of diabetic patients is 415 million. By 2040, according to analysts of the International Diabetes Federation, the number of the sick increases and the disease will affect 1 in 10 people. It is ex...

Bibliografski detalji
Glavni autori:	A. S. Ametov, E. V. Doskina
Format:	Članak
Jezik:	Russian
Izdano:	Remedium Group LLC 2017-07-01
Serija:	Медицинский совет
Teme:	diabetes mellitus type 2 inhibitors dpp 4 alogliptin cardioesophageal efficiency
Online pristup:	https://www.med-sovet.pro/jour/article/view/1933

Slični predmeti

CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
od: N. A. Petunina, i dr.
Izdano: (2017-12-01)

Alogliptin – the new member of DPP-4 inhibitors class
od: Nina Aleksandrovna Petunina, i dr.
Izdano: (2014-12-01)

Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
od: M. V. Shestakova, i dr.
Izdano: (2021-07-01)

Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring
od: Arumugam Kodimuthali, i dr.
Izdano: (2010-07-01)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
od: Xu Liu, i dr.
Izdano: (2021-09-01)

Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin
od: N. A. Petunina, i dr.
Izdano: (2019-01-01)

Remitting Seronegative Symmetrical Synovitis and Pitting Edema Syndrome After Administration of a Dipeptidyl Peptidase-4 Inhibitor, Alogliptin, in a Patient With Type 2 Diabetes
od: Shota Mochizuki, i dr.
Izdano: (2022-07-01)

Alogliptin: efficiency, safety, new possibilities
od: L. Yu. Morgunov
Izdano: (2020-05-01)

Cardiovascular safety in the treatment of diabetes mellitus type 2: focus on alogliptin
od: A. L. Terekhova, i dr.
Izdano: (2016-12-01)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
od: Hae Jin Kim, i dr.
Izdano: (2022-09-01)

PREDICTION OF ANTI-DIABETIC ALOGLIPTIN STABILITY BY ISOTHERMAL STUDIES
od: Charise Dallazem Bertol, i dr.
Izdano: (2023-10-01)

Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective
od: Faraha Ahmed, i dr.
Izdano: (2025-02-01)

Formulation and Optimization of Alogliptin-Loaded Polymeric Nanoparticles: In Vitro to In Vivo Assessment
od: Dibyalochan Mohanty, i dr.
Izdano: (2022-07-01)

Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
od: Ji-Yeon Park, i dr.
Izdano: (2024-09-01)

Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial
od: João Pedro Ferreira, i dr.
Izdano: (2020-06-01)

Salting-out induced liquid–liquid microextraction for alogliptin benzoate determination in human plasma by HPLC/UV
od: Sherin F. Hammad, i dr.
Izdano: (2021-01-01)

Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report
od: Noda Yoko, i dr.
Izdano: (2013-01-01)

Utility of picric acid and 2,4 dinitrophenol as chromogenic reagents for visible spectrophotometric quantification of alogliptin
od: A.V.V.N.K. Sunil Kumar, i dr.
Izdano: (2017-06-01)

A developed HPLC method for the determination of Alogliptin Benzoate and its potential impurities in bulk drug and tablets
od: Kun Zhang, i dr.
Izdano: (2015-04-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
od: Alexander Sergeevich Ametov, i dr.
Izdano: (2010-06-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
od: Yayoi Nishida, i dr.
Izdano: (2020-04-01)

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
od: Georgii Rubenovich Khachatryan, i dr.
Izdano: (2015-09-01)

Enantioselective Box Behenken Optimized HPLC-DAD Method for the Simultaneous Estimation of Alogliptin Enantiomorphs in Pharmaceutical For mulations and their Pharmacokinetic Study in Rat Plasma
od: Ravi Kant, i dr.
Izdano: (2019-02-01)

Investigation of Alogliptin-Loaded In Situ Gel Implants by 2<sup>3</sup> Factorial Design with Glycemic Assessment in Rats
od: Tarek M. Ibrahim, i dr.
Izdano: (2022-09-01)

SURGICAL PALLIATIVE AND SYMPTOMATIC TREATMENT OF REGIONAL CANCER OF THE CARDIOESOPHAGEAL JUNCTION
od: R. A. Khvastunov, i dr.
Izdano: (2017-01-01)

Combined Treatment for Locally Advanced Cardioesophageal Cancer in a Comorbid Patient with Internal Carotid Artery Stenosis
od: S. A. Domrachev, i dr.
Izdano: (2025-01-01)

Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment
od: S. К. Zyryanov, i dr.
Izdano: (2025-02-01)

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
od: Alexander Sergeevich Ametov, i dr.
Izdano: (2011-09-01)

DIPEPTIDYL DIPEPTIDASE-4: VIEW OF THE CLINICAL PHARMACOLOGIST
od: N. B. LAZAREVA
Izdano: (2016-12-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
od: Editorial team Diabetes Mellitus
Izdano: (2012-06-01)

Early and Chronic Dipeptidyl‐Peptidase‐IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial
od: Abhinav Sharma, i dr.
Izdano: (2018-06-01)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
od: Hyun Min Kim, i dr.
Izdano: (2015-03-01)

Aripiprazole cardiosafety: Is it overestimated?
od: Ahmed Naguy
Izdano: (2016-01-01)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
od: Yury Ivanovich Suntsov
Izdano: (2012-03-01)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
od: Ghosh S, i dr.
Izdano: (2016-11-01)

Control of type 2 diabetes mellitus: problems and prospects for their solution
od: Tatiana Ivanovna Romantsova, i dr.
Izdano: (2009-12-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
od: Antonio Asti, i dr.
Izdano: (2016-03-01)

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
od: M. V. Shestakova, i dr.
Izdano: (2023-12-01)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
od: Cobble Michael E, i dr.
Izdano: (2012-01-01)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
od: Marina Vladimirovna Shestakova
Izdano: (2010-09-01)